Monday, September 10, 2018

Sept. 9, 2018
Richard Sackler and his billionaire family, who have been blamed for fostering the nation's ongoing opioid epidemic, own a second pharmaceutical company.
The Sacklers are the owners of Purdue Pharma, which created the addictive opioid painkiller OxyContin. But the family also own a second company based in Rhode Island, Rhodes Pharma, according to a Financial Times report released Sunday.
Rhodes Pharma is of one of the largest creators of off-patent generic opioids. The company produces several opioid-based painkillers that contain addictive drugs including oxycodone, hydrocodone and morphine.
The Sacklers are worth a combined $13 billion, according to a 2016 Forbes report. The vast majority of their wealth, shared among 20 family members, is derived from drug-making.
Purdue Pharma has faced hundreds of lawsuits over the years for fueling the opioid epidemic. More than 63,000 people in the U.S. died from drug overdoses in 2016, of which 66 percent were related to opioid use.
The Sackler family was also recently found to be behind a new drug aimed to help treat opioid addiction known as Buprenorphine-water, the Washington Post reported.§ion=Health
Sept. 8, 2018
One of the world’s top breast cancer doctors failed to disclose millions of dollars in payments from drug and health care companies in recent years, omitting his financial ties from dozens of research articles in prestigious publications like The New England Journal of Medicine and The Lancet.
The researcher, Dr. José Baselga, a towering figure in the cancer world, is the chief medical officer at Memorial Sloan Kettering Cancer Center in New York. He has held board memberships or advisory roles with Roche and Bristol-Myers Squibb, among other corporations, has had a stake in start-ups testing cancer therapies, and played a key role in the development of breakthrough drugs that have revolutionized treatments for breast cancer.
According to an analysis by The New York Times and ProPublica, Dr. Baselga did not follow financial disclosure rules set by the American Association for Cancer Research when he was president of the group. He also left out payments he received from companies connected to cancer research in his articles published in the group’s journal, Cancer Discovery. At the same time, he has been one of the journal’s two editors in chief.
At a conference this year and before analysts in 2017, he put a positive spin on the results of two Roche-sponsored clinical trials that many others considered disappointments, without disclosing his relationship to the company. Since 2014, he has received more than $3 million from Roche in consulting fees and for his stake in a company it acquired.
Dr. Baselga did not dispute his relationships with at least a dozen companies. In an interview, he said the disclosure lapses were unintentional.
Sept. 8, 2018
GOP Senator Ben Sasse Admits Trump ‘Regularly’ Makes Him Want To Leave The Republican Party
“He is accelerating the trend, obviously,” the Nebraska senator said. “But it didn’t start two years ago.”

No comments:

Post a Comment